Novavax, Inc.
NVAX
$8.05
-$0.09-1.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.70M | 139.51M | 147.14M | 70.45M | 239.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.70M | 139.51M | 147.14M | 70.45M | 239.24M |
| Cost of Revenue | 72.29M | 112.43M | 135.96M | 103.70M | 80.29M |
| Gross Profit | -15.59M | 27.09M | 11.18M | -33.26M | 158.95M |
| SG&A Expenses | 35.21M | 37.12M | -9.76M | 46.12M | 53.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.50M | 149.54M | 126.20M | 149.83M | 133.57M |
| Operating Income | -50.81M | -10.03M | 20.94M | -79.38M | 105.67M |
| Income Before Tax | -51.68M | -8.51M | 17.90M | -203.04M | 107.45M |
| Income Tax Expenses | 1.71M | 985.00K | 376.00K | -657.00K | 946.00K |
| Earnings from Continuing Operations | -53.39M | -9.49M | 17.53M | -202.38M | 106.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.39M | -9.49M | 17.53M | -202.38M | 106.51M |
| EBIT | -50.81M | -10.03M | 20.94M | -79.38M | 105.67M |
| EBITDA | -47.75M | -6.97M | 26.06M | -72.80M | 113.23M |
| EPS Basic | -0.32 | -0.06 | 0.11 | -1.25 | 0.66 |
| Normalized Basic EPS | -0.18 | -0.01 | 0.11 | -0.29 | 0.43 |
| EPS Diluted | -0.32 | -0.06 | 0.11 | -1.25 | 0.62 |
| Normalized Diluted EPS | -0.18 | -0.01 | 0.11 | -0.29 | 0.40 |
| Average Basic Shares Outstanding | 164.57M | 163.28M | 162.53M | 162.35M | 162.02M |
| Average Diluted Shares Outstanding | 164.57M | 163.28M | 165.18M | 162.35M | 177.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |